Sugi Predict

Sugi Predict / Compounds / SCHEMBL2133357

SCHEMBL2133357

SCHEMBL2133357

CCc1cc(OCc2ccccc2)ccc1Br

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 11/20 0.54
▸ ALOX5 P09917 1/20 0.53
▸ BCHE P06276 1/20 0.50
▸ TOP1 P11387 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ MAOA P21397 4/20 0.48
▸ GSTP1 P09211 1/20 0.47
▸ CA12 O43570 1/20 0.47
▸ CA1 P00915 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ CA4 P22748 1/20 0.47
▸ CA5A P35218 1/20 0.47
▸ CA7 P43166 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ CA5B Q9Y2D0 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ PTGS1 P23219 1/20 0.47
▸ SLC6A2 P23975 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29925382 1.00 MAOB (0.54) MAOBALOX5BCHETOP1L3MBTL1
SCHEMBL3920931 0.88 MAOB (0.51) MAOBALOX5BCHELMNACYP1A2
SCHEMBL5708162 0.87 MAOB (0.46) MAOBALOX5TOP1MAOAGSTP1
SCHEMBL5214953 0.86 MAOB (0.50) MAOBALOX5BCHELMNACYP1A2
SCHEMBL2434378 0.84 MAOB (0.51) MAOBALOX5BCHEL3MBTL1LMNA
SCHEMBL31748829 0.84 MAOB (0.54) MAOBALOX5GSTP1LMNACYP1A2
SCHEMBL28120154 0.84 MAOB (0.56) MAOBALOX5TOP1L3MBTL1MAOA
SCHEMBL3918694 0.84 FFAR1 (0.47) MAOBBCHEL3MBTL1MAOA
SCHEMBL28866139 0.84 MAOB (0.54) MAOBALOX5TOP1L3MBTL1MAOA
SCHEMBL16863738 0.83 MAOB (0.50) MAOBALOX5BCHETOP1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235719-A1 DIMERIC SMAC MIMETICS USEFUL IN HIV THERAPY VIIV HEALTHCARE COMPANY (US) 2025-11-13 — — WO disclosed
WO-2025217560-A1 TRIAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2025-10-16 — — WO disclosed
US-12398135-B2 Dimethyl amino azetidine amides as JAK inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2025-08-26 — — US disclosed
US-20250034131-A1 DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS THERAVANCE BIOPHARMA R&D IP LLC (US) 2025-01-30 — — US disclosed
EP-4114836-B1 CRYSTALLINE HYDRATE OF A JAK INHIBITOR COMPOUND THERAVANCE BIOPHARMA R&D IP LLC (US) 2025-01-08 — — EP disclosed
US-12122773-B2 Crystalline hydrate of a JAK inhibitor compound THERAVANCE BIOPHARMA R&D IP, LLC (US) 2024-10-22 — — US disclosed
EP-3837258-B1 DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS THERAVANCE BIOPHARMA R&D IP LLC (US) 2024-04-24 — — EP disclosed
US-20240025897-A1 CRYSTALLINE HYDRATE OF A JAK INHIBITOR COMPOUND THERAVANCE BIOPHARMA R&D IP LLC (US) 2024-01-25 — — US disclosed
US-20240025897-A1 CRYSTALLINE HYDRATE OF A JAK INHIBITOR COMPOUND THERAVANCE BIOPHARMA R&D IP LLC (US) 2024-01-25 — — US disclosed
CN-112739697-B Dimethylaminoazetidine amides as JAK inhibitors 施万生物制药研发IP有限责任公司 2023-10-20 — — CN disclosed
EP-1537091-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2005-06-08 — — EP disclosed
WO-2005019151-A1 PPAR MODULATORS ELI LILLY AND COMPANY (US) 2005-03-03 — — WO disclosed
US-6809110-B2 NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID HOFFMANN-LA ROCHE INC. 2004-10-26 — — US disclosed
US-20040157898-A1 Novel substituted oxazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 2004-08-12 — — US disclosed
WO-2004063155-A1 FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2004-07-29 — — WO disclosed
US-20040116487-A1 Novel oxazole derivatives HOFFMANN-LA ROCHE INC. 2004-06-17 — — US disclosed
US-20040110807-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2004-06-10 — — US disclosed
WO-2004041275-A1 SUBSTITUTED 4-ALKOXYOXAZOL DERIVATIVES AS PPAR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-05-21 — — WO disclosed
WO-2004031162-A1 CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-04-15 — — WO disclosed
WO-2004020420-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2004-03-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034131-A1 DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS JAK1, JAK2, JAK3 MAOB 2057/4885ALOX5 1493/4885BCHE 4048/4885
US-12398135-B2 Dimethyl amino azetidine amides as JAK inhibitors JAK1, JAK2, JAK3 MAOB 2057/4885ALOX5 1493/4885BCHE 4048/4885
US-12122773-B2 Crystalline hydrate of a JAK inhibitor compound JAK1, JAK2, JAK3 MAOB 4094/4885ALOX5 3314/4885BCHE 4788/4885
US-20040157898-A1 Novel substituted oxazole derivatives OXA1L, SLC5A1, GPR119 MAOB 2146/4885ALOX5 1096/4885BCHE 2541/4885
US-20240025897-A1 CRYSTALLINE HYDRATE OF A JAK INHIBITOR COMPOUND JAK1, JAK2, JAK3 MAOB 4094/4885ALOX5 3314/4885BCHE 4788/4885
US-20040110807-A1 Thiazole derivatives SLC5A1, GPR119, INSR MAOB 4027/4885ALOX5 3343/4885BCHE 3739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.